Supply Chain/Logistics

May 03, 2012
By BioPharm International Editors
The UK's Medicines and Healthcare products Regulatory Agency has launched a new anticounterfeiting strategy with the aim of curbing the occurrence of falsified medicines in the county's supply chain.
May 01, 2012
BioPharm International
No matter the time or cost, knowing what's going on inside your facilities is always going to be worth the effort.
Nov 22, 2011
BioPharm International
By BioPharm International Editors
The EMA released a concept paper for consultation on Nov. 8, 2011, that recommends a revision to Annex 16 of the Guide to Good Manufacturing of Medicinal Products to address more complicated global supply chains and new falsified medicines legislation. Since Annex 16 was introduced in 2001, a number of positive and negative trends have occurred in the pharmaceutical industry. In particular, confusion has arisen over the role of the qualified person (QP), and harmonization of requirements has been lost between member states. The EMA cites several commonly asked questions within the concept paper:
Jul 01, 2011
BioPharm International
Incorporating regulatory requirements into the product life cycle is crucial.
May 01, 2011
BioPharm International
Addressing supply-chain challenges.
Apr 12, 2011
BioPharm International
Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs
Jun 18, 2010
Vetter held a groundbreaking ceremony for its new facility in Ravensburg.
Jun 01, 2010
BioPharm International
International outsourcing and rising theft spur regulatory action and manufacturer oversight.
Apr 01, 2010
BioPharm International
The ability to deal with the complexity of the clinical supply process has shifted the balance of power to clinical supply chain specialists.
Mar 01, 2010
BioPharm International
Sharing information is a critical part of security—whether we're protecting travelers from bombs or patients from adulterated medicines.
native1_300x100
lorem ipsum